Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.

Slides:



Advertisements
Similar presentations
Briefing on MHRA routine inspection of non-commercial clinical trials
Advertisements

Tips to a Successful Monitoring Visit
Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
PREPARATION FOR FDA INSPECTION
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
HIPAA Basic Training for Privacy & Information Security Vanderbilt University Medical Center VUMC HIPAA Website:
AUDITS Process and Corrective Actions OIG RolesGAO ROLES – OIG –OIG Lead Auditor –OCFO – owner of MATS and Agency Audit Process –OEI AA – Designated OEI.
FERPA The Family Educational Rights and Privacy Act.
BY: GROUP 2 Food Safety Regulations and Standards.
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Incident Reporting Procedure
Audits and Inspections in Clinical Research Jobin Kunjumon Vilapurathu.
How To Prepare For A CIP Audit Scott Barker CISSP, CISA CIP Compliance Workshop Baltimore, MD August 19-20, 2009.
FDA 483 and Warning Letter Interpretation with real Case Studies
Monitoring, Audits, and Inspection Oh my! Rachel Sheppard Regulatory Director, OCRSS.
1. Objectives  Describe the responsibilities and procedures for reporting and investigating ◦ incidents / near-miss incidents ◦ spills, releases, ◦ injuries,
© Business & Legal Reports, Inc OSHA Inspections, Citations, and Penalties Massachusetts Care Self-Insurance Group, Inc. S afety A wareness F or.
1 Hosting an FDA Inspection: A Field Investigator ’ s Perspective Presented by Mihaly S. Ligmond Consumer Safety Officer US Food and Drug Administration,
1 Thank you for visiting our site and welcome to the “Introduction to ISO 22000” Presentation that you requested. For more information.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
1 Optimal Strategies for Preparing Integrated and Clinical Summaries for a New Drug Application: Making it Work Under Any Circumstance Lisa A. Pierchala,
Bayesian approach to equivalence study of medical device 1 1.
Preparing for an Audit Roy De Lauder CPPM, CF NOVA Chapter General Dynamics Advanced Information Systems.
MHRA Inspection Readiness By Lulu Cvetkovic NICR QA Manager.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.
Draft White Paper “Protocol Deviations”
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Briefing on MHRA routine inspection of non-commercial clinical trials
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
- A “Portable” Implementation
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Presenter Title Organization
Track 11 Symposium 27 June :30 – 3:00 PM
Perspective on GCP Warning Letters
Implementing a Successful Corrective and Preventative Action Program
Understanding EU GDPR from an Office 365 perspective
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
FDA Inspections Stephen Joseph Joy’s Quality Management Systems
Visitor GMP Policy Reception Staff Responsibilities SOP
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Sponsor-Investigator (SI) FDA Inspections
Presenter Name Title Organization.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
Presentation transcript:

Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners. 2

GOING BACK IN TIME  1978 – Final FDA GLP Regulations  1987 – Final Revised FDA GLP Regulations That is 34 years, and 25 years ago… and yet…

Form FDA 483 Failure to document… Failure to document… Documentation was incomplete… Documentation was incomplete… Results were not included in the report… Results were not included in the report… Records were falsified… Records were falsified… (2010)

GLP

Testing Facility Management failed to…Testing Facility Management failed to… The Study Director failed to…The Study Director failed to… The Quality Assurance Unit failed to…The Quality Assurance Unit failed to… You failed to…You failed to… (2010)

Knock-knock ! What now ? Too late to prepare !!!

PREPARATION Know the GLP regulations!Know the GLP regulations! SOP on regulatory inspectionsSOP on regulatory inspections Training of personnel for inspectionTraining of personnel for inspection Manual at receptionManual at reception Mock FDA inspectionMock FDA inspection Know what to do ! Train and rehearse !

SOPs to Address Facility Security and ReceptionFacility Security and Reception GLP Coordinator dutiesGLP Coordinator duties Escort processEscort process Records requestsRecords requests Photocopy processPhotocopy process Facility tour and questions to staffFacility tour and questions to staff

Security and Reception “This is FDA.”  May I see your credentials ?  Please sign visitor log.  Please wait so I can notify.  This way to a conference room.

OPENING CONFERENCE IntroductionsIntroductions Review credentialsReview credentials Inspection scopeInspection scope FDA Form 482FDA Form 482 Schedule (calendar, hours)Schedule (calendar, hours) Escort expectationsEscort expectations Location of bathroom and coffee/tea/waterLocation of bathroom and coffee/tea/water

SPONSORS NOTIFICATION if You’re a CRO  Studies on FDA Form 482  Notify the sponsor first and get permission!!!  Where are the study data archived ?  Where are samples and specimens archived ?

FACILITY TOUR  Led by GLP Coordinator  Prevent: –Compromise of ongoing work –Disturbance of animals –Contamination of test articles –Health hazard to inspector (& others)

Handling Inspection Questions Assume a courteous and cooperative attitude Always be positive and patient Do not become argumentative Be prepared to admit mistakes where appropriate Don’t try to answer questions for someone else’s data if you aren’t sure Only answer the question ask Never lie or try to cover up

QUESTIONS TO STAFF Answers controlled by GLP CoordinatorAnswers controlled by GLP Coordinator Redirect question to appropriate personRedirect question to appropriate person Rephrase question if not clearRephrase question if not clear Lead response if off trackLead response if off track Interrupt answer as soon as completeInterrupt answer as soon as complete

STAFF ANSWERS Only answer when qualifiedOnly answer when qualified –Qualifications –Current duties –Knowledge of company SOPs –Tasks and assignments performed If not sure, ask GLP Coordinator’s helpIf not sure, ask GLP Coordinator’s help Refer to SOP when appropriateRefer to SOP when appropriate

EXIT CONFERENCE  If no FDA Form 483… thank inspectors –Do NOT open new issues !  If FDA Form 483… thank inspectors –Solicit details and boundaries –Clarify basis from regulation –Discuss possible corrections –Present corrections implemented –Discuss schedule for responses

RESPONSE TO EIR  EIR reviewed by FDA Management Any finding is now official positionAny finding is now official position  Warning Letter (or Private Letter) may be issued before or after EIR  Respond to all issues in EIR, if issued first

WARNING LETTER

RESPONSE TO WARNING LETTER  Respond quickly  Respond completely  Finalize corrective actions  Document all responses  Review responses… (QAU audit ?)

CLOSURE Implement all corrective actions FDA will come back !

Knock-knock !